Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the writing committee of the american society for apheresis
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TLDR
This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria.Abstract:
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007 ASFA Special Issue (Fourth Edition), the committee has incorporated systematic review and evidence‐based approach in the grading and categorization of indications. This Sixth Edition of the ASFA Special Issue has further improved the process of using evidence‐based medicine in the recommendations by consistently applying the category and GRADE system definitions, but eliminating the “level of evidence” criteria (from the University HealthCare Consortium) utilized in prior editions given redundancy between GRADE and University HealthCare Consortium systems. The general layout and concept of a fact sheet that was utilized in the Fourth and Fifth Editions, has been largely maintained in this edition. Each fact sheet succinctly summarizes the evidence for the use of therapeutic apheresis in a specific disease entity. This article consists of 78 fact sheets (increased from 2010) for therapeutic indications in ASFA categories I through IV, with many diseases categorized having multiple clinical presentations/situations which are individually graded and categorized. J. Clin. Apheresis 28:145–284, 2013. © 2013 Wiley Periodicals, Inc.read more
Citations
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Michael Walsh,Peter A. Merkel,Chen-Au Peh,Wladimir Szpirt,Xavier Puéchal,Shouichi Fujimoto,Carmel M. Hawley,Nader Khalidi,Oliver Floßmann,Ron Wald,Louis Girard,Adeera Levin,Gina Gregorini,Lorraine Harper,William F. Clark,Christian Pagnoux,Ulrich Specks,Lucy Smyth,Vladimir Tesar,Toshiko Ito-Ihara,Toshiko Ito-Ihara,Janak de Zoysa,Wojciech Szczeklik,Luis Felipe Flores-Suárez,Simon Carette,L. Guillevin,Charles D. Pusey,Alina Casian,Biljana Brezina,Andrea Mazzetti,Carol A. McAlear,Elizabeth Broadhurst,Donna Reidlinger,Samir Mehta,Natalie Ives,David Jayne,Pexivas Investigators Pexivas Investigators +36 more
TL;DR: Among patients with severe ANCA-associated vasculitis, the use of plasma exchange did not reduce the incidence of death or ESKD, and a reduced-dose regimen of glucocorticoids was noninferior to a standard- dose regimen with respect to death orESKD.
Journal ArticleDOI
Current knowledge of hypertriglyceridemic pancreatitis.
TL;DR: There is a definite need for an international, multicenter approach to the management of severe hypertriglyceridemia, due to the lack of randomized and controlled trials if plasmapheresis may improve morbidity and mortality in the clinical setting of HTG-AP.
Journal ArticleDOI
Immunopathogenesis and treatment of cytokine storm in COVID-19.
Jaeseok Kim,Jun Young Lee,Jae Won Yang,Keum Hwa Lee,Maria Effenberger,Wladimir Szpirt,Andreas Kronbichler,Jae Il Shin +7 more
TL;DR: The potential therapeutic role of extracorporeal cytokine removal to treat the cytokine storm associated with COVID-19 is discussed and expectations are especially high for new cytokine-targeted therapies, such as tocilizumab, anakinra, and baricitinib.
Journal ArticleDOI
Introduction to Special Issue: Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 7th Edition
Joseph E. Schwartz,Anand Padmanabhan,Nicole A. Aqui,Rasheed A. Balogun,Laura Connelly-Smith,Meghan Delaney,Nancy M. Dunbar,Volker Witt,Yanyun Wu,Beth H. Shaz,Beth H. Shaz,Beth H. Shaz +11 more
References
More filters
Journal ArticleDOI
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.
Journal ArticleDOI
High density lipoprotein as a protective factor against coronary heart disease: The Framingham study
TL;DR: The major potent lipid risk factor was HDL cholesterol, which had an inverse association with the incidence of coronary heart disease in either men or women and these associations were equally significant even when other lipids and other standard risk factors for coronaryHeart disease were taken into consideration.
Journal Article
A novel MHC class-I-like gene is mutated in patients with hereditary haemochromatosis
TL;DR: Using linkage–disequilibrium and full haplotype analysis, a region more than 3 megabases telomeric of the major histocompatibility complex (MHC) that is identical–by–descent in 85% of patient chromosomes is identified, containing a gene related to the MHC class I family, termed HLA–H, containing two missense alterations.
Journal ArticleDOI
Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study
Maarten J. Titulaer,Lindsey McCracken,Iñigo Gabilondo,Thaís Armangue,Carol A. Glaser,Takahiro Iizuka,Lawrence S. Honig,Susanne M. Benseler,Izumi Kawachi,Eugenia Martinez-Hernandez,Eugenia Martinez-Hernandez,Esther Aguilar,Nuria Gresa-Arribas,Nicole Ryan-Florance,Abiguei Torrents,Albert Saiz,Myrna R. Rosenfeld,Myrna R. Rosenfeld,Rita J. Balice-Gordon,Francesc Graus,Josep Dalmau,Josep Dalmau,Josep Dalmau +22 more
TL;DR: Most patients with anti-NMDAR encephalitis respond to immunotherapy; second-line immunotherapy is usually effective when first-line treatments fail, and outcomes continued to improve for up to 18 months after symptom onset.
Journal ArticleDOI
Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma
Josep Dalmau,Erdem Tüzün,Hai-Yan Wu,Jaime Masjuan,Jeffrey E. Rossi,Alfredo Voloschin,Joachim M. Baehring,Haruo Shimazaki,Reiji Koide,Dale King,Warren P. Mason,Lauren H Sansing,Marc A. Dichter,Myrna R. Rosenfeld,David A. Lynch +14 more
TL;DR: The autoantigens of a new category of treatment‐responsive paraneoplastic encephalitis are reported, and it is proposed that this category should be combined with existing treatment-responsive encephalopathy categories.